$0.81
+0.07 (+9.06%)
Open$0.75
Previous Close$0.74
Day High$0.86
Day Low$0.75
52W High$12.00
52W Low$6.44
Volume—
Avg Volume281.9K
Market Cap6.58M
P/E Ratio25.19
EPS$0.42
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+1,434.4% upside
Current
$0.81
$0.81
Target
$12.39
$12.39
$9.33
$12.39 avg
$15.15
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.16M | 3.05M | 3.43M |
| Net Income | -41,291 | -50,098 | -44,694 |
| Profit Margin | -1.3% | -1.6% | -1.3% |
| EBITDA | -71,807 | -61,818 | -76,890 |
| Free Cash Flow | -34,920 | -36,621 | -42,296 |
| Rev Growth | +21.0% | -5.0% | +24.8% |
| Debt/Equity | 0.35 | 0.39 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |